Insight, Strategy, Execution

We Guide Biotech Through The Big Moments

Taking the next step in genomic medicine

New brand and website for a biotech preparing to enter the clinic

HC Bioscience

View Story

A Rare Moment

Partnering with X4 Pharmaceuticals, Inc. in its first FDA approval in rare disease

X4 Pharmaceuticals, Inc.

View Story

Absolute Precision

Clasp Therapeutics

View Story

MAKING HISTORY

A Landmark for Genome Editing

INTELLIA Therapeutics

View Story

Team

Work

Recent Headlines

Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Booster Therapeutics Launches to Pioneer New Class of Proteasome Activator Medicines for the Treatment of a Range of Complex Diseases

Meet the BostInno 2024 Fire Awards honorees

The 2024 PharmaVoice 100: Li Peng

Endpoints News Announces the 2024 Winners of the Endpoints 11 Awards, Highlighting Biotech’s Most Promising Startups

Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

Vividion Therapeutics to Expand with New Global Research and Development Center

SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

Passion Growth Collaboration

Our team is deeply engaged with the biotech world, attuned to the latest developments and always looking around the corner to anticipate where the industry is moving.

Life At Ten Bridge